Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications

N-myc 介导的髓母细胞瘤中翻译组的重塑及其治疗意义

基本信息

  • 批准号:
    10522626
  • 负责人:
  • 金额:
    $ 66.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

Medulloblastoma is the most common malignant pediatric brain tumor. After surgery, radiation and chemotherapy, five-year survival is 60-70% overall. Survivors show severe physical and cognitive disabilities, often unable to live independently. Medulloblastoma exists in four distinct molecular subgroups (WNT, SHH, Group3, Group 4). An incurable subgroup of SHH driven tumors show amplification of the MYCN transcription factor. How can we target N-myc in medulloblastoma? N-myc’s ability to regulate protein synthesis is tied both to its oncogenic potential and to interactions with the mTOR serine-threonine kinase. We hypothesize that N- myc hijacks the translational machinery regulated by the mTOR serine threonine kinase to drive transformation; and that targeting translation control represents a therapeutic strategy for N-myc driven cancers. Employing ribosome profiling technology, we surprisingly found that in addition to roles as a global regulator of protein synthesis, N-myc interacts with mTOR to regulate translation of 13 mRNAs belonging to the folding machinery, functionally important for N-myc driven medulloblastoma. The mechanisms by which N-myc directs the translation of these specific subsets of mRNAs to drive tumorigenesis and whether these potential vulnerabilities can be leveraged to develop targeted therapies remain outstanding questions. In this proposal, we will mechanistically dissect how N-myc hijacks the translational machinery for its oncogenic activity. Using novel genetic approaches, we will separately evaluate the importance of eIF4E and eIF4A in our N-myc driven genetically engineered mouse (GEM) models. We will also test new clinical drugs against eIF4A and eIF4E, analyzing GEM models, and patient derived orthotopic xenografts. Successful completion of these aims will delineate how N-myc interacts with mTOR to regulate key subsets of translational targets, and elucidates druggable mechanisms in N-myc driven medulloblastoma.
髓母细胞瘤是小儿最常见的恶性脑肿瘤。经过手术、放疗和 化疗,五年生存率为60-70%。幸存者表现出严重的身体和认知障碍, 往往无法独立生活。髓母细胞瘤存在于四个不同的分子亚群(WNT,SHH, 组3、组4)。一个无法治愈的SHH驱动的肿瘤亚组显示MYCN转录扩增 因子我们如何在髓母细胞瘤中靶向N-myc?N-myc调节蛋白质合成的能力与 其致癌潜力和与mTOR丝氨酸-苏氨酸激酶的相互作用。我们假设N- myc劫持由mTOR丝氨酸苏氨酸激酶调节的翻译机制以驱动转化; 并且靶向翻译控制代表了N-myc驱动的癌症的治疗策略。采用 核糖体分析技术,我们惊讶地发现,除了作为蛋白质的全球调节器的作用, 在合成中,N-myc与mTOR相互作用以调节属于折叠机器的13种mRNA的翻译, 对于N-myc驱动的髓母细胞瘤功能重要。N-myc基因调控细胞凋亡的机制 翻译这些特定的mRNA子集来驱动肿瘤发生,以及这些潜在的脆弱性是否 如何利用这些技术来开发靶向治疗仍然是一个悬而未决的问题。在本提案中,我们将 机械地剖析N-myc如何劫持其致癌活性的翻译机制。使用新颖 我们将分别评估eIF 4 E和eIF 4A在我们的N-myc驱动的基因表达中的重要性。 基因工程小鼠(GEM)模型。我们还将测试针对eIF 4A和eIF 4 E的新临床药物, 分析GEM模型和患者来源的原位异种移植物。成功实现这些目标将 描述N-myc如何与mTOR相互作用以调节翻译靶点的关键子集,并阐明 在N-myc驱动的髓母细胞瘤中的药物机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Davide Ruggero其他文献

Davide Ruggero的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Davide Ruggero', 18)}}的其他基金

ERa is a novel RNA-binding protein controlling breast cancer
ERa是一种新型RNA结合蛋白,可控制乳腺癌
  • 批准号:
    10580061
  • 财政年份:
    2022
  • 资助金额:
    $ 66.62万
  • 项目类别:
ERa is a novel RNA-binding protein controlling breast cancer
ERa是一种新型RNA结合蛋白,可控制乳腺癌
  • 批准号:
    10460857
  • 财政年份:
    2022
  • 资助金额:
    $ 66.62万
  • 项目类别:
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications
N-myc 介导的髓母细胞瘤中翻译组的重塑及其治疗意义
  • 批准号:
    10672311
  • 财政年份:
    2022
  • 资助金额:
    $ 66.62万
  • 项目类别:
Mechanisms of regulated translation control in cancer and its therapeutic implications
癌症中翻译控制的调节机制及其治疗意义
  • 批准号:
    10664866
  • 财政年份:
    2019
  • 资助金额:
    $ 66.62万
  • 项目类别:
Mechanisms of regulated translation control in cancer and its therapeutic implications
癌症中翻译控制的调节机制及其治疗意义
  • 批准号:
    10226938
  • 财政年份:
    2019
  • 资助金额:
    $ 66.62万
  • 项目类别:
Mechanisms of regulated translation control in cancer and its therapeutic implications
癌症中翻译控制的调节机制及其治疗意义
  • 批准号:
    10436946
  • 财政年份:
    2019
  • 资助金额:
    $ 66.62万
  • 项目类别:
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
致癌应激反应和癌症中 eF4E 依赖性翻译控制
  • 批准号:
    9265424
  • 财政年份:
    2014
  • 资助金额:
    $ 66.62万
  • 项目类别:
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
致癌应激反应和癌症中 eF4E 依赖性翻译控制
  • 批准号:
    8674344
  • 财政年份:
    2014
  • 资助金额:
    $ 66.62万
  • 项目类别:
MYCN, mTOR and translation control in medulloblastoma
髓母细胞瘤中的 MYCN、mTOR 和翻译控制
  • 批准号:
    9304355
  • 财政年份:
    2014
  • 资助金额:
    $ 66.62万
  • 项目类别:
Diversity Supplement for MYCN, mTOR and translation control in medulloblastoma
髓母细胞瘤中 MYCN、mTOR 和翻译控制的多样性补充
  • 批准号:
    9067800
  • 财政年份:
    2014
  • 资助金额:
    $ 66.62万
  • 项目类别:

相似海外基金

Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
  • 批准号:
    573541-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 66.62万
  • 项目类别:
    University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
  • 批准号:
    2744317
  • 财政年份:
    2022
  • 资助金额:
    $ 66.62万
  • 项目类别:
    Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
  • 批准号:
    MR/V010948/1
  • 财政年份:
    2021
  • 资助金额:
    $ 66.62万
  • 项目类别:
    Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
  • 批准号:
    10019570
  • 财政年份:
    2019
  • 资助金额:
    $ 66.62万
  • 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
  • 批准号:
    10223370
  • 财政年份:
    2019
  • 资助金额:
    $ 66.62万
  • 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
  • 批准号:
    10455108
  • 财政年份:
    2019
  • 资助金额:
    $ 66.62万
  • 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
  • 批准号:
    255762
  • 财政年份:
    2012
  • 资助金额:
    $ 66.62万
  • 项目类别:
    Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
  • 批准号:
    20790351
  • 财政年份:
    2008
  • 资助金额:
    $ 66.62万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
  • 批准号:
    19370021
  • 财政年份:
    2007
  • 资助金额:
    $ 66.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
  • 批准号:
    7131841
  • 财政年份:
    2006
  • 资助金额:
    $ 66.62万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了